Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
References
Additional references
Abramson JH, Abramson ZH. Making Sense of Data: A Self‐instruction Manual on the Interpretation of Epidemiological Data. 3rd Edition. New York: Oxford University Press, 2001.
Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers’ Handbook 4.2.2 (updated December 2003), Appendix 5b. http://www.cochrane.org/resources/handbook/hbook.htm2003.
Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa‐dependent coagulation in hemophilia blood (Comment). Blood 2002;100(1):364‐5.
Clarke M, Oxman A. Cochrane Reviewers' Handbook 4.2 [updated March 2003]. In: The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Chichester: Wiley, 2003; Vol. Issue 3.
Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Medicine 2002;28(Supplement 2):S248‐55. [MEDLINE: 12404094]
Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M. Effect of recombinant activated factor VIIa on perioperative blood loss in patients undergoing retropubic prostatectomy: a double‐blind, placebo‐controlled randomised trial. Lancet 2003;361(9353):201‐5. [MEDLINE: 12547542]
Hedner U, Erhardtsen E. Potential role for rVIIa in transfusion medicine. Transfusion 2002;42(1):114‐24. [MEDLINE: 11896322]
Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001;71(3):402‐5. [MEDLINE: 11233901]
Key NS, Mast AE. Factor VIIa and tissue factor pathway inhibitor. In: Stowell C, Dzik W editor(s). Emerging Technologies in Transfusion Medicine. AABB Press, 2003.
Key NS. Recombinant FVIIa for intractable hemorrhage: more questions than answers. Transfusion 2003;43(12):1649‐51.
Lodge P, Jonas S, Jaeck D, Fridberg MJ. Recombinant factor VIIa (Novoseven) in partial hepatectomy: a randomized placebo‐controlled, double‐blinded clinical trial. Hepatology. 2002; Vol. 36:211A.
Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM. A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4(6):790‐8.
Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, Macaitis JM, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. Journal of Trauma 2001;50(4):721‐9. [MEDLINE: 11303171]
O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP. Recombinant factor VIIa in the management of uncontrolled hemorrhage. Transfusion 2003;43(12):1711‐6. [MEDLINE: 14641868]
Planinsic RM. Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multi‐center study. Hepatology. 2002; Vol. 36:660A.
Roberts HR. Recombinant factor VIIa (NovoSeven) and the safety of treatment. Seminars in Haematology 2001;4(Supplement 12):48‐50.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273:408‐12.
